Company news
Guardant Health, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
March 9, 2023
Musa Tariq Joins Guardant Health Board of Directors
February 26, 2023
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
February 22, 2023
Guardant Health to Participate in Upcoming March Investor Conferences
February 16, 2023
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
February 14, 2023
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
February 7, 2023
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
February 1, 2023
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
February 1, 2023
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
January 31, 2023
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
January 30, 2023
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
January 29, 2023
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
January 18, 2023
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
January 16, 2023
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
January 8, 2023
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
December 20, 2022
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
December 14, 2022
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
December 7, 2022
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
November 30, 2022
Guardant Health Reports Third Quarter 2022 Financial Results
November 2, 2022
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
October 9, 2022
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
September 8, 2022
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
September 5, 2022
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
August 30, 2022
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
August 28, 2022
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
August 14, 2022
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
August 11, 2022
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
August 4, 2022
Guardant Health Reports Second Quarter 2022 Financial Results
August 3, 2022
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
August 1, 2022
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
July 12, 2022
Steve E. Krognes Joins Guardant Health Board of Directors
July 6, 2022
Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China
July 5, 2022
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
June 12, 2022
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
May 20, 2022
Guardant Health Reports First Quarter 2022 Financial Results
May 4, 2022
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
May 1, 2022
Guardant Health to Report First Quarter Financial Results on May 5, 2022
April 12, 2022
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
April 10, 2022
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
April 3, 2022
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
March 13, 2022
Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test
March 7, 2022
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
February 22, 2022
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
January 17, 2022
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
December 16, 2021
Guardant Health Reports Third Quarter 2021 Financial Results
November 3, 2021
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
November 2, 2021
Guardant Health Appoints Myrtle Potter to Its Board of Directors
October 19, 2021
Guardant Health to Report Third Quarter Financial Results on November 4, 2021
October 7, 2021
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
October 4, 2021
Calls
The 5 newest of 26 calls. Every call is listed under its year.
- Guardant Health (NASDAQ:GH) Q3 2026 Earnings Call
Nov 5, 2026
Transcript - Guardant Health (NASDAQ:GH) Q2 2026 Earnings Call
Jul 30, 2026
Transcript - Guardant Health (NASDAQ:GH) Q1 2026 Earnings Call
May 7, 2026
Transcript - Guardant Health (NASDAQ:GH) Q3 2025 Earnings Call
Oct 29, 2025
Transcript - Guardant Health (NASDAQ:GH) Q2 2025 Earnings Call
Jul 30, 2025
Transcript
Decks
The 5 newest of 49 decks. Every deck is listed under its year.
- Q3 2026 Earnings Presentation
Earnings · 28 slides · Nov 5, 2026
- Q2 2026 Earnings Presentation
Earnings · 25 slides · Jul 30, 2026
- William Blair 46th Annual Growth Stock Conference (June 2026)
Conference · 26 slides · Jun 2, 2026
- Q1 2026 Earnings Presentation
Earnings · 24 slides · May 7, 2026
- Fact Sheet (April 2026)
Fact sheet · 1 slide · April 2026